APR January/February 2022 - 82

Pharmaceutical
P.I.N.
Points
Patent Innovation News
The purpose of this column is to highlight
and summarize recent key patents in the
pharmaceutical arena issued by the US
Patent Office in October-November 2021.
Neelam Sharma, MS, Lavanya Kundurthy,
and Hemant N. Joshi, PhD, MBA*
Tara Innovations, LLC
www.tarainovations.com and www.tara-marketing.com
*hemantjoshi@tarainnovations.com
Compositions and Methods for
Treating SARS-CoV-2 Infections;
V. C. Bond, M.B. Huang, and J.W. Lillard, Jr.;
Morehouse School of Medicine, US; U.S.
Patent # 11,180,534; November 23, 2021.
This application relates to methods for treating viral infections. More
particularly, to an antiviral composition comprising a multipartite
virus inhibiting secretion modulating region (VI-SMR) peptide for
treatment and prevention of SARS-CoV-2 viral infections. A method
for treating a SARS-CoV-2 infection or reducing the viral load
comprises administering to the subject infected with SARS-CoV-2
an effective amount of a pharmaceutical composition comprising
a VI-SMR peptide comprising an SMR peptide from HIV-1 Nef in
combination with a CPP, a Clu-BP, or both, where the VI-SMR peptide
further comprises an anti-SARS-CoV-2 AF peptide, an anti-SARSCoV-2
VAI peptide, or both. A method for reducing viral load in a
SARS-CoV-2 infected patient can result in at least a 2 or 3 log.sub.10
reduction in viral RNA copies per mg of lung tissue compared to a
negative control.
Methods for Improving Safety of
Blood-Brain Barrier Transport;
R.J. Watts, J. Yu Zuchero, J. Couch
and M. Dennis; Genentech, Inc.,
US; U.S. Patent # 11,167,038;
November 9, 2021.
The blood vessels that vascularize the central nervous
system (CNS) possess a unique property, termed the blood-
brain barrier (BBB). BBB allows these vessels to tightly
regulate the movement of ions, molecules between the
blood and the brain. Brain penetration of large molecule
drugs is severely limited by impermeable BBB. Utilizing
transcytosis trafficking pathways of endogenous receptors
expressed at the brain capillary endothelium is one way
to overcome the BBB obstacle. Monoclonal antibodies
have been designed towards these receptors to enable
receptor-mediated delivery of large molecules to the brain.
However, the safety of administration of such antibodies
and conjugates has not been fully understood. The
present invention relates to compositions and methods for
improving the safety of BBB receptor-mediated transport.
Composition for Enteric Hard
Capsule and Method for Producing
Enteric Hard Capsule; N. Maruyama;
Shin-Etsu Chemical Co. Ltd., Japan; U.S.
Patent # 11,141,381; October 12, 2021.
Gelatin or HPMC capsules are unsuitable for pharmaceutical
products which are unstable in an acid or irritate the stomach. In
such cases, hard capsules with enteric polymer coating are used.
But this additional coating step results in low productivity and high
cost. To address this problem, a hard capsule has been developed
by using an enteric polymer itself as a capsule base material. Each
conventional method of producing enteric hard capsules requires
a water-soluble gelling agent. There is a problem that the resulting
enteric capsules exhibit an insufficient water resistance or acid
resistance. This patent provides a method for producing an enteric
hard capsule by taking advantage of conventionally unknown
thermal gelation characteristics of a neutralized aqueous solution
of an enteric polymer. The resulting enteric capsule shows sufficient
water resistance and acid resistance. The inventors have found that
certain HPMCAS' have excellent thermal gelation characteristics. The
HPMCAS' having a particular substitution degree is used as the base
material for an enteric hard capsule.
82 |
| January/February 2022
http://www.tarainovations.com http://www.tara-marketing.com

APR January/February 2022

Table of Contents for the Digital Edition of APR January/February 2022

APR January/February 2022 - Cover1
APR January/February 2022 - Cover2
APR January/February 2022 - 1
APR January/February 2022 - 2
APR January/February 2022 - 3
APR January/February 2022 - 4
APR January/February 2022 - 5
APR January/February 2022 - 6
APR January/February 2022 - 7
APR January/February 2022 - 8
APR January/February 2022 - 9
APR January/February 2022 - 10
APR January/February 2022 - 11
APR January/February 2022 - 12
APR January/February 2022 - 13
APR January/February 2022 - 14
APR January/February 2022 - 15
APR January/February 2022 - 16
APR January/February 2022 - 17
APR January/February 2022 - 18
APR January/February 2022 - 19
APR January/February 2022 - 20
APR January/February 2022 - 21
APR January/February 2022 - 22
APR January/February 2022 - 23
APR January/February 2022 - 24
APR January/February 2022 - 25
APR January/February 2022 - 26
APR January/February 2022 - 27
APR January/February 2022 - 28
APR January/February 2022 - 29
APR January/February 2022 - 30
APR January/February 2022 - 31
APR January/February 2022 - 32
APR January/February 2022 - 33
APR January/February 2022 - 34
APR January/February 2022 - 35
APR January/February 2022 - 36
APR January/February 2022 - 37
APR January/February 2022 - 38
APR January/February 2022 - 39
APR January/February 2022 - 40
APR January/February 2022 - 41
APR January/February 2022 - 42
APR January/February 2022 - 43
APR January/February 2022 - 44
APR January/February 2022 - 45
APR January/February 2022 - 46
APR January/February 2022 - 47
APR January/February 2022 - 48
APR January/February 2022 - 49
APR January/February 2022 - 50
APR January/February 2022 - 51
APR January/February 2022 - 52
APR January/February 2022 - 53
APR January/February 2022 - 54
APR January/February 2022 - 55
APR January/February 2022 - 56
APR January/February 2022 - 57
APR January/February 2022 - 58
APR January/February 2022 - 59
APR January/February 2022 - 60
APR January/February 2022 - 61
APR January/February 2022 - 62
APR January/February 2022 - 63
APR January/February 2022 - 64
APR January/February 2022 - 65
APR January/February 2022 - 66
APR January/February 2022 - 67
APR January/February 2022 - 68
APR January/February 2022 - 69
APR January/February 2022 - 70
APR January/February 2022 - 71
APR January/February 2022 - 72
APR January/February 2022 - 73
APR January/February 2022 - 74
APR January/February 2022 - 75
APR January/February 2022 - 76
APR January/February 2022 - 77
APR January/February 2022 - 78
APR January/February 2022 - 79
APR January/February 2022 - 80
APR January/February 2022 - 81
APR January/February 2022 - 82
APR January/February 2022 - 83
APR January/February 2022 - 84
APR January/February 2022 - Cover3
APR January/February 2022 - Cover4
https://www.nxtbookmedia.com